Tr eatment o f focal segmental glomerulosclerosis (FSGS) is one of the major challenges in the field o f pediatric nephrology. T he disease is responsible for 10 to 15 percent of pediatric end-stage renal disease (ESRD).1 O nly about 15 percent o f patients with FSGS respond to conventional oral glucocorticoid therapy. T he remaining 85 percent, who are steroid resistant, carry a high risk of developing ESRD.2'4 T he best indicator o f outcome o f FSGS is the response to steroid therapy.4 M any o f the patients who responded initially eventually became steroid resistant.5 Uncontrolled trials during the past decade have suggested that the disease is not as unresponsive to all treatm ent as previously thought. 4, 6 M any drug regimens have been used in the treatm ent o f FSGS with variable success.3,5,7 ' 9 In what could be described as an extremely aggressive course of treatment, methylprednisolone infusion along with oral prednisone for 12 m onths was used with complete remission in more than 50 percent o f patients. However, this treatm ent carried a high risk o f side effects. 3, 8 T he cumulative experience in patients with steroid resistant FSGS treated with cyclosporin A has not been impressive. 4 Cytotoxic therapy has only rarely been beneficial in patients who are steroid resistant.5 Partial response to cyclophosphamide leads to improvement in the clinical outcome o f many steroid-resistant nephrotic patients with FSGS.9 However, the use o f oral cyclophosphamide (OCP) is complicated by attendant side effects.10 Intravenous cyclophosphamide (IVCP) has been extensively used in lupus nephritis and various vasculitic disorders and has been shown to be an effective form o f therapy with significantly fewer side-effects than OCP.1113 IVCP has been successfully used in steroid-resistant minimal change nephritic syndrome with minimal side effects.14 In the present study, we report the response o f 15 steroid-resistant FSGS patients to IVCP and the outcome after 4 years o f follow up.
Patients and Methods
T he study group was composed o f 15 children (10 male, 5 female) who fulfilled the following inclusion criteria: (1) age at onset of 1 to 12 years, (2) evidence of steroid resistance by the presence of heavy proteinuria (>40 mg/m2/hr) despite 4 weeks of standard prednisolone therapy (60 mg/m2/day), (3) hypoalbuminemia (25 mg/dL), (4) renal biopsy showing FSGS, (5) absence of identifiable medical diseases associated with FSGS, (6) no prior treatment with cytotoxic or immunosuppressive agents other than steroids, (7) a normal serum creatinine for age, and (8) informed consent provided for IVCP treatment.
The renal biopsies were examined by two independent pathologists. T he extent o f glomerular sclerosis, interstitial inflammation, interstitial fibrosis and tubular atrophy were determined. Interstitial and tubular changes were described as mild ( 10% of biopsy material examined), moderate (10-50%) and severe (51% ). The presence of IgM deposits was determined by immunofluorescence. Five patients had been resistant to initial therapy with 60 mg/m2 of daily prednisone administered for 4 weeks. Their proteinuria remained in the nephrotic range with persistent, hypoalbuminemia and edema. They were considered steroid resistant initially. The other ten patients had initially gone into remission within four weeks of 60 mg/m2 daily prednisone therapy, but had suffered from frequent relapses later, and eventually became steroid resistant with nephrotic-range proteinuria while on 60 mg/m2 daily steroid for a further 4 weeks. They were considered late steroid resistant.
The patients were started on monthly infusions o f IVCP at a dose of 500 m g/m2 for 6 months. IVCP was administered as an infusion in 250 mL of normal saline over 3 to 4 hours. A high oral fluid intake was ensured for the following 24 hours to promote frequent voiding of dilute urine to minimize the risk of hemorrhagic cystitis. To minimize bladder toxicity further, the patients received 2-mercaptoethane sulfonate sodium (MESZNA) during the first 12 hours after cyclophosphamide infusion. Adjunctive prednisolone was given in a dose o f 60 m g/m 2/day for 4 weeks followed by 40 mg/m2/per on alternate days for 4 weeks and then tapered off over the next 4 weeks, unless the patient showed steroid dependency.
The children were followed up monthly for the first 6 months and every 3 months thereafter or whenever medical care was needed. The parents were given instructions to do a urine dipstick test for protein at home once per week. O n each visit the child was evaluated clinically for evidence o f disease activity and complications. We measured the urine albumin to creatinine ratio in a spot sample, serum albumin, creatinine, hemoglobin and the total leukocyte count. The children were monitored for infections, leucopenia, cataracts, and alopecia. In the presence of infection or leucopenia, the next dose of IVCP was delayed until complete normalization of the count or recovery from infections. The response to IVCP by the end of six months was defined as: (i) complete remission (no or trace proteinuria on urine dipstick, or urine spot albumin to creatinine ratio <0.2, increase in serum albumin >3.5 g/dL, complete resolution of edema), (ii) steroid dependency (complete resolution but proteinuria during steroid tapering), (iii) non-response (persistent edema, hypoalbuminemia and proteinuria of 4+ on urine dipstick or urine spot albumin to creatinine ratio of > 0.2 by the end of 6 months o f IVCP). The proteinuria-free period post IVCP was calculated from the time o f completion o f IVCP protocol (6th dose) to the occurrence of the first relapse. The final outcome after 4 years o f observation was classified as (1) sustained remission (complete remission in the last year o f observation) (2) frequent relapses (3) steroid dependent (4) non-response (no response to IVCP and patient continue to be steroid resistant). The glomerular filtration rate (GFR) was estimated using the modified height formula of Schwartz.15 A G FR > 80 mL/min per 1.73 m 2 was considered normal.
Results
The observation period of post-treatment follow-up was 4 years for each patient. None of the patients had renal failure prior to starting IVCR By the end of the observation period, ten patients were steroid dependent and five patients were steroid resistant ( Table 1 ). All the five patients who had an initial resistance to steroids showed no response to IVCP They continued to be steroid resistant, with three of them developing CRF during the observation period and one of requiring chronic peritoneal dialysis. Four of the non-responding patients received other alkylating agents and IV methylprednisolone with no response. The fifth patient was given I.V methyl prednisolone pulses with no response; she was not given other alkylating agents as her renal failure deteriorated rapidly. Her older brother had ESRD secondary to FSGS. There were ten patients who respond to IVCP The response started after the 2nd dose o f IVCP. In this group o f responders, five patients achieved relatively prolonged remission (7 months to 24 months), but later developed frequent relapses that were treated with oral prednisone similar to the course during IVCP treatment; however, they suffered from frequent relapses and eventually become steroid dependent by the end o f the observation period. They were maintained on prednisone 0.5-0.8 mg/kg per alternate day. The other five patients who responded and became steroid sensitive could not be weaned from the steroid, and continued to be steroid dependent by the end o f the four years o f observation.
There was no significant difference in the histopathological findings in the group o f patients who showed response to IVCP compared to non-responders (Table 1) . IgM deposits were positive in only 2 patients o f the non-responder group and 5 patients o f the responder group. Similarly, there was no significant difference between males and females in response to IVCP. Non-responder patients were o f extreme age at presentation. The youngest and oldest (1 year and 8 years) in the group had CRF at the end o f the observation period.
The side-effects o f cyclophosphamide were minimal. Some patients developed nausea and vomiting in the first 24 
Discussion
Although alkylating agents, specifically cyclophosphamide and chlorambucil, have minimal efficacy in children w ith FSGS who have shown resistance to glucocorticoid treatm ent,5 they still widely used as an alternative to or in com bination with glucocorticoids.6 They spare the patient from large cumulative doses o f glucocorticoid, which provoke unwanted adverse effects.3 It is widely believed that concurrent use o f an alkylating agent during glucocorticoid treatm ent increases the probability o f inducing remission. 4 Most authors agree that the duration o f remission induced by an alkylating agent is roughly proportional to the length o f the course o f treatm ent.14 However, the potential side effects o f these drugs limit their use. Leucopenia, chemical cystitis, alopecia and sterility pose considerable problems in patients exposed to prolonged courses o f OCP.2,4 A com bination o f pulse methylprednisolone and O C P has been advocated, but prolonged patient hospitalization and steroid side effects such as hypertension, cataract, and growth retardation limit their use.2-4 7 In IVCP-induced and sustained remission in children with steroid-resistant minimal change nephrotic syndrome, one study showed a better outcome than prolonged treatm ent with OCP.14 The total IVCP dose used was lower than the oral dose at 2 mg/kg daily for 8 weeks. The author did not report any adverse effect o f IVCP therapy. Rennert et al16 reported the use o f IVCP in ten patients with steroid resistant FSGS who had promising results as sustained remission was achieved in 70 percent o f the patients. However, the follow-up period was short.
In our study, IVCP was found to be effective in late responders. The outcome in initially steroid-resistant patients was poor; none o f the five patients responded to IVCP and three progressed to renal failure. This result is similar to the outcome in patients who used O C P 4,5 We could not determine a predictive value of the percentage o f glomeruli with segmental sclerosis in terms o f response to IVCP and final outcome. The presence o f IgM deposits on the biopsy specimen were not related to the eventual response to the treatment. This support the results o f other studies that could not find clear correlations between the extent o f sclerosis or IgM deposition and progression o f FSGS or its response to therapy. 2 4 W ith this modality o f treatment, 67 percent o f our patients who were steroid resistant before IVCP become steroid dependent. This improvement in the clinical outcome may help patients with steroid-resistant FSGS. The cumulative doses given were far below those considered toxic. The side effects of IVCP were negligible. Patients with initial steroid resistance did not respond. Beneficial therapy for this group of patients remains to be determined.
